Chronic Urticaria Pipeline: Unleashing Hope with 20+ Innovators like UCB Biopharma, GI Innovation, Celldex Therapeutics, and Eli Lilly Crafting Bold New Therapies

The chronic urticaria or hives market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Novartis, Synermore Biologics, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Celltrion, and United BioPharma. These industry pioneers are transforming treatment strategies and redefining the future of Chronic Urticaria or Hives care, bringing new hope to patients worldwide.

DelveInsight's 'Chronic Urticaria Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Chronic Urticaria or Hives therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Chronic Urticaria or Hives pipeline domain.

For emerging Chronic Urticaria or Hives drugs, the Chronic Urticaria or Hives pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Chronic Urticaria or Hives Pipeline Report
• DelveInsight's Chronic Urticaria or Hives Pipeline analysis depicts a robust space with 20+ active players working to develop 22+ pipeline drugs for Chronic Urticaria or Hives treatment.
• The leading Chronic Urticaria or Hives companies include Novartis, Synermore Biologics, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Celltrion, United BioPharma, Glenmark Pharmaceuticals, UCB Biopharma, GI Innovation, Celldex Therapeutics, Eli Lilly and Company, Amgen, ValenzaBio, Third Harmonic Bio, Inmagene, Lanier Biotherapeutics, and others are evaluating their lead assets to improve the Chronic Urticaria or Hives treatment landscape.
• Key Chronic Urticaria or Hives pipeline therapies in various stages of development include SYN008, Povorcitinib, Briquilimab, Remibrutinib, DUPIXENT, FASENRA, Lirentelimab, TEZSPIRE, Rilzabrutinib, TAS5315, Barzolvolimab, and others.
• In November 2024, the FDA accepted the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 and older with chronic spontaneous urticaria (CSU) inadequately controlled by H1 antihistamines.

Request a sample and discover the recent breakthroughs happening in the Chronic Urticaria or Hives pipeline landscape @ https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chronic Urticaria or Hives Overview
Chronic urticaria (CU) is a skin condition marked by hives or wheals lasting over six weeks, causing persistent itching and discomfort that impacts quality of life. It may be idiopathic or linked to underlying issues. Symptoms include raised, itchy welts that vary in size and location, intense itching (often worse at night), swelling (angioedema) around the eyes, lips, or throat, and frequent hives for weeks. Triggers can involve autoimmune factors (autoantibodies activating histamine release), physical stimuli (pressure, temperature, exercise), infections (e.g., Helicobacter pylori), rare allergens, or conditions like thyroid disease or lupus.

CU's pathophysiology involves immune cells like mast cells and basophils releasing histamine and inflammatory cytokines (e.g., IL-4, IL-13), causing vasodilation, swelling, and itching. Autoantibodies may target IgE receptors in some cases. Diagnosis relies on patient history and physical exams, assessing hive duration, triggers, and symptoms. Tests like CBC, ESR, thyroid function, or ASST may identify underlying causes.

Treatment starts with non-sedating H1 antihistamines, escalating to H2 antihistamines or leukotriene antagonists if needed. Severe cases may require omalizumab or immunosuppressants like cyclosporine. Short-term corticosteroids help acute flares, but long-term use is avoided. Avoiding triggers is key.

Find out more about Chronic Urticaria or Hives medication @ https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chronic Urticaria or Hives Treatment Analysis: Drug Profile
SYN008: Synermore Biologics
SYN008 is a biosimilar to Omalizumab (Xolair), a humanized monoclonal antibody targeting free IgE in the blood. By binding IgE, it prevents its interaction with effector cells, halting allergic responses regardless of the allergen. Extensive comparability studies with Omalizumab were completed, and an investigational new drug (IND) application was submitted to the China Food and Drug Administration (CFDA) in October 2014. Phase I trials concluded in Australia by September 2016, and SYN008 is now in Phase III development for treating chronic urticaria.

Povorcitinib: Incyte Corporation
Povorcitinib (INCB54707) is an oral, selective JAK1 inhibitor currently in Phase III trials for hidradenitis suppurativa (HS) and vitiligo, with a Phase III trial planned for prurigo nodularis (PN). It is also under evaluation in Phase II studies for PN, asthma, and chronic spontaneous urticaria. Protected by compound and use patents in select regions, povorcitinib is in Phase II development for chronic urticaria treatment.

Key Chronic Urticaria or Hives Therapies and Companies
• SYN008: Synermore Biologics
• Povorcitinib - Incyte Corporation
• Briquilimab: Jasper Therapeutics
• Remibrutinib (LOU064): Novartis Pharmaceuticals
• DUPIXENT (dupilumab): Sanofi/Regeneron
• FASENRA (benralizumab): AstraZeneca/Kyowa Hakko Kirin
• Lirentelimab (AK002): Allakos/BioWa
• TEZSPIRE (tezepelumab): AstraZeneca/Amgen
• Rilzabrutinib (SAR444671): Sanofi
• TAS5315: Taiho Pharmaceutical
• Barzolvolimab (CDX-0159): Celldex Therapeutics

Learn more about the novel and emerging Chronic Urticaria or Hives pipeline therapies @ https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chronic Urticaria or Hives Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Chronic Urticaria or Hives Pipeline Report
• Coverage: Global
• Key Chronic Urticaria or Hives Companies: Novartis, Synermore Biologics, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Celltrion, United BioPharma, Glenmark Pharmaceuticals, UCB Biopharma, GI Innovation, Celldex Therapeutics, Eli Lilly and Company, Amgen, ValenzaBio, Third Harmonic Bio, Inmagene, Lanier Biotherapeutics, and others.
• Key Chronic Urticaria or Hives Pipeline Therapies: SYN008, Povorcitinib, Briquilimab, Remibrutinib, DUPIXENT, FASENRA, Lirentelimab, TEZSPIRE, Rilzabrutinib, TAS5315, Barzolvolimab, and others.

Dive deep into rich insights for drugs used for Chronic Urticaria or Hives treatment; visit @ https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Urticaria or Hives Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chronic Urticaria or Hives Pipeline Therapeutics
6. Chronic Urticaria or Hives Pipeline: Late-Stage Products (Phase III)
7. Chronic Urticaria or Hives Pipeline: Late-Stage Products (Phase III)
8. Chronic Urticaria or Hives Pipeline: Mid-Stage Products (Phase II)
9. Chronic Urticaria or Hives Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.